Cleveland Clinic at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Cleveland Clinic brings 2 presentations to ASH 2026 in New Orleans, and exhibits at Booth 131. Its program spans chronic myeloid leukemia, venous blood clots and bispecific antibodies for myeloma in community practice. It also asks who needs extended treatment for venous thromboembolism and at what dose, and what inflammasome inhibitors offer where clonal hematopoiesis meets thrombosis.
| Organization | ASH 2026 Attendance |
|---|---|
Cleveland Clinic Cleveland, OH | |
Nonprofit academic medical center in Cleveland, Ohio; its Taussig Cancer Institute offers blood cancer care, stem cell transplant and CAR T-cell therapy. | Booth Exhibiting at Booth 131 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00am–10:00am Breaking News: Launching Bispecific Antibodies for Multiple Myeloma in Community Practice Bringing bispecific antibodies for multiple myeloma into community clinics, with patient selection, sequencing, toxicity management, and outpatient setup. Talk Role of Inflammasome Inhibitors in the Intersection of CH and Thrombosis Drugs that block the inflammasome and interleukin-1 signaling as a way to prevent clots and heart disease in people with clonal hematopoiesis. Session Balancing Bleeding and Clotting: Extended VTE Treatment for Whom and at What Dose? Longer-term anticoagulation for cancer-associated blood clots after the first six months, using new randomized trials to guide who continues and at what dose. |
Instantly find 20 buyers from Cleveland Clinic
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction